Antibody Response Post-COVID-19 Vaccination in Patients With Chronic Myeloid Leukemia With Comparison Between Comirnaty and CoronaVac Vaccine
Dear Editor Chronic myeloid leukemia (CML) is a type of myeloproliferative neoplasm characterized by an oncogenic fusion gene, BCR-ABL1. Most CML patients present at chronic phase, ~90%,1 when BCR-ABL1 tyrosine kinase inhibitor (TKI) is the recommended first-line treatment. Antibody response afte...
Saved in:
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | en |
| Published: |
SAGE Publications Inc.
2022
|
| Subjects: | |
| Online Access: | http://ir.unimas.my/id/eprint/38986/1/Antibody%20Response%20Post-COVID-19%20Vaccination%20in%20Patients%20With%20Chronic%20Myeloid%20Leukemia%20With%20Comparison%20Between%20Comirnaty%20and%20CoronaVac%20Vaccine.pdf http://ir.unimas.my/id/eprint/38986/ https://journals.sagepub.com/doi/abs/10.1177/10105395221112836?journalCode=apha |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | Dear Editor
Chronic myeloid leukemia (CML) is a type of myeloproliferative neoplasm characterized by an oncogenic fusion gene, BCR-ABL1. Most CML patients present at chronic phase, ~90%,1 when BCR-ABL1 tyrosine kinase inhibitor (TKI) is the recommended first-line treatment. Antibody response
after severe acute respiratory syndrome coronavirus 2
(SARS-CoV-2) vaccination in CML patients is concerned
due to probable CML-induced and/or TKI-induced immunosuppression. To our knowledge, two studies reported antibody response post-SARS-CoV-2 vaccine in CML patients.2,3 A study reported anti-spike SARS-CoV-2 IgG (IgG-S) responses > 14 days after a dose of Comirnaty (Comirnaty or BNT162b2, Pfizer-BioNTech) (n = 1) or ChAdOx1
(ChAdOx1 nCoV-19 or AZD1222, AstraZeneca-Oxford) (n
= 11) vaccine.2 Seroconversion rate post-ChAdOx1 was
lower than control group, 8/11 (73%) versus 58/63 (92%).2
A study reported response 3 weeks after a dose of Comirnaty (n = 16) using a different laboratory methodology.3 |
|---|